Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
MorphoSys AG announced that shareholders approved all resolutions at its 2024 Annual General Meeting, including a merger squeeze-out of minority shareholders. The key points are:
1. Minority shareholders' shares will be transferred to Novartis BidCo Germany AG, the majority shareholder.
2. Cash compensation set at €68.00 per share.
3. The squeeze-out becomes effective upon registration in commercial registers of both MorphoSys and Novartis.
4. The virtual meeting had 92.43% representation of MorphoSys' share capital.
5. All proposed resolutions by the Management Board and Supervisory Board were approved.
MorphoSys AG ha annunciato che gli azionisti hanno approvato tutte le delibere durante l'Assemblea Generale Annuale del 2024, inclusa una fusione di esclusione dei soci di minoranza. I punti chiave sono:
1. Le azioni degli azionisti di minoranza saranno trasferite a Novartis BidCo Germany AG, l'azionista di maggioranza.
2. Risarcimento in denaro fissato a €68,00 per azione.
3. L'esclusione diventa efficace al momento della registrazione nei registri commerciali sia di MorphoSys che di Novartis.
4. La riunione virtuale ha avuto una rappresentanza del 92,43% del capitale azionario di MorphoSys.
5. Tutte le risoluzioni proposte dal Consiglio di Amministrazione e dal Consiglio di Sorveglianza sono state approvate.
MorphoSys AG anunció que los accionistas aprobaron todas las resoluciones en su Junta General Anual de 2024, incluyendo una exclusión de fusión de los accionistas minoritarios. Los puntos clave son:
1. Las acciones de los accionistas minoritarios serán transferidas a Novartis BidCo Germany AG, el accionista mayoritario.
2. Compensación en efectivo fijada en €68,00 por acción.
3. La exclusión se vuelve efectiva al momento de la inscripción en los registros comerciales de MorphoSys y Novartis.
4. La reunión virtual tuvo una representación del 92,43% del capital social de MorphoSys.
5. Todas las resoluciones propuestas por la Junta Directiva y el Consejo de Supervisión fueron aprobadas.
MorphoSys AG는 주주들이 2024년 정기 주주총회에서 모든 결의안을 승인했다고 발표했으며, 여기에는 소수 주주들의 합병 배제가 포함됩니다. 주요 사항은 다음과 같습니다:
1. 소수 주주들의 주식은 다수 주주인 Novartis BidCo Germany AG에게 이전됩니다.
2. 주당 현금 보상은 €68.00으로 설정되었습니다.
3. 배제는 MorphoSys와 Novartis의 상업 등록부에 등록되면 효력이 발생합니다.
4. 가상 회의에서는 MorphoSys의 자본금에 대해 92.43%의 대표성이 있었습니다.
5. 경영 이사회와 감독 이사회가 제안한 모든 결의안이 승인되었습니다.
MorphoSys AG a annoncé que les actionnaires ont approuvé toutes les résolutions lors de son Assemblée Générale Annuelle de 2024, y compris un rachat de fusion des actionnaires minoritaires. Les points clés sont :
1. Les actions des actionnaires minoritaires seront transférées à Novartis BidCo Germany AG, l'actionnaire majoritaire.
2. Indemnité en espèces fixée à 68,00 € par action.
3. Le rachat entre en vigueur dès son inscription dans les registres commerciaux de MorphoSys et Novartis.
4. La réunion virtuelle a eu une représentation de 92,43% du capital social de MorphoSys.
5. Toutes les résolutions proposées par le Conseil d'administration et le Conseil de surveillance ont été approuvées.
MorphoSys AG gab bekannt, dass die Aktionäre auf der ordentlichen Hauptversammlung 2024 alle Beschlüsse genehmigten, einschließlich einer Mergersqueeze-out der Minderheitsaktionäre. Die wichtigsten Punkte sind:
1. Die Anteile der Minderheitsaktionäre werden an Novartis BidCo Germany AG, den Mehrheitsaktionär, übertragen.
2. Die Barausgleichszahlung beträgt 68,00 € pro Aktie.
3. Der Squeeze-out wird nach der Eintragung in die Handelsregister von MorphoSys und Novartis wirksam.
4. Die virtuelle Versammlung hatte eine Vertretung von 92,43% des Grundkapitals von MorphoSys.
5. Alle vorgeschlagenen Beschlüsse des Vorstands und des Aufsichtsrats wurden genehmigt.
- Successful approval of all proposed resolutions at the Annual General Meeting
- High shareholder participation with 92.43% of share capital represented
- Cash compensation of €68.00 per share for minority shareholders in the squeeze-out
- Loss of minority shareholder ownership in MorphoSys AG
- Potential delisting from stock exchanges following the merger squeeze-out
The approval of the merger squeeze-out is a significant development for MorphoSys shareholders. The
The merger squeeze-out approval at MorphoSys' AGM is a pivotal legal event. This process, governed by German corporate law, allows a majority shareholder (Novartis) to compulsorily acquire minority shares, effectively delisting the company. The
The MorphoSys squeeze-out approval signifies a notable shift in the biotech landscape. This move by Novartis reflects a broader trend of big pharma consolidating smaller, innovative biotech firms to bolster their pipelines. The
MUNICH, GERMANY / ACCESSWIRE / August 27, 2024 / MorphoSys AG today announced that its shareholders approved all resolutions proposed by the company's Management Board and Supervisory Board at its 2024 Annual General Meeting. This included the transfer of MorphoSys' minority shareholders' shares to Novartis BidCo Germany AG (hereinafter referred to as "Novartis"), the company's majority shareholder, against a cash compensation of € 68.00 per share ("merger squeeze-out"). The merger squeeze-out will become effective once the transfer resolution and merger have been registered in the commercial register of MorphoSys, and the merger has also been registered in the commercial register of Novartis.
The 2024 Annual General Meeting was held on August 27, 2024, with
More information on MorphoSys' 2024 Annual General Meeting can be found at www.morphosys.com/agm.
About MorphoSys
At MorphoSys, we are driven by our mission: More life for people with cancer. As a global biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at www.morphosys.com and follow us on Twitter at X and LinkedIn.
Forward-Looking Statements
This communication contains certain forward-looking statements concerning MorphoSys, Novartis and the merger squeeze-out that involve substantial risks and uncertainties. Forward-looking statements include any statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "goal," "may," "might," "plan," "predict," "project," "seek," "target," "potential," "will," "would," "could," "should," "continue" and similar expressions. In this communication, MorphoSys' forward-looking statements include statements about the consummation of the merger squeeze-out; MorphoSys' plans, objectives, expectations and intentions; and the financial condition, results of operations and business of MorphoSys and Novartis AG.
The forward-looking statements contained in this communication represent the judgment of MorphoSys as of the date of this communication and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: the effects of the acquisition of MorphoSys by Novartis AG on relationships with employees, other business partners or governmental entities; that Novartis BidCo AG and Novartis AG may not realize the potential benefits of the acquisition of MorphoSys by Novartis AG; potential operational difficulties with integrating MorphoSys with Novartis AG; that MorphoSys' expectations may be incorrect; the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements; MorphoSys' reliance on collaborations with third parties; estimating the commercial potential of MorphoSys' development programs; and other risks indicated in the risk factors included in MorphoSys' filings with the SEC, including MorphoSys' Annual Report on Form 20-F. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this communication. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this communication to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
For more information, please contact:
| |
Media Contacts: | Investor Contacts: |
|
|
SOURCE: MorphoSys AG
View the original press release on accesswire.com
FAQ
What was the main decision made at MorphoSys AG's 2024 Annual General Meeting?
How much of MorphoSys AG's share capital was represented at the 2024 Annual General Meeting?
When will the MorphoSys AG (MOR) merger squeeze-out become effective?
What is the cash compensation offered to MorphoSys AG (MOR) minority shareholders in the squeeze-out?
